Flindr Therapeutics Raises €20 Million for Precision Oncology Therapies

Flindr Therapeutics' Series A Funding

Key Highlights:

• Series A Funding: Flindr Therapeutics, a precision oncology therapeutics company, raised €20 million in Series A funding.
• Investor Syndicate: Funding was led by V-Bio Ventures, with participation from JJDC, QBIC Fund, Flanders Future Tech Fund, Curie Capital, and existing investors.
• Precision Oncology Treatments: Flindr Therapeutics is developing precision oncology therapies using its ImmunoGram Drug Discovery Engine, focusing on identifying important drug targets involved in patient clinical response.
• Lead Program: Flindr's lead program is a small molecule inhibitor of RNF31, a protein-stabilizing E3 ubiquitin ligase aberrantly activated in solid and hematological malignancies.

Flindr Therapeutics' Target Market

• Target Market: Precision oncology treatments cater to patients with various types of cancer, including solid and hematological malignancies.
• Oncology Specialists and Researchers: Collaboration opportunities with oncologists and researchers in the field of precision oncology.
• Pharmaceutical Companies: Potential partnerships with pharmaceutical companies interested in developing precision oncology therapies.

What Flindr Therapeutics Needs to Buy

• Research and Development Services: Collaborations with research organizations and laboratories to further develop precision oncology therapies.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers to produce small molecule inhibitors and manage the supply chain.
• Regulatory and Clinical Expertise: Access to regulatory and clinical experts to navigate the process of obtaining IND and conducting clinical trials.